Targeted proteomics-determined multi-biomarker profiles developed classifier for prognosis and immunotherapy responses of advanced cervical cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Xu,Zhang

第一单位： NHC Key Laboratory of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China.

作者： Xu,Zhang ^[1] ; Jin,Li ^[2] ; Liuke,Yang ^[3] ; Youwei,Zhu ^[4] ; Rongrong,Gao ^[5] ; Tiancheng,Zhang ^[6] ; Xuwen,Chen ^[7] ; Jun,Fu ^[1] ; Gaoyang,He ^[2] ; Huijuan,Shi ^[8] ; Shenjie,Peng ^[9] ; XiaoHua,Wu ^[9]

作者单位： NHC Key Laboratory of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China. ^[1] Shanghai-MOST Key Laboratory of Health and Disease Genomics, NHC Key Laboratory of Reproduction Regulation, Shanghai Institute for Biomedical and Pharmaceutical Technologies, Shanghai, China. ^[2] Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China. ^[3] Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. ^[4] College of Plant Protection, Nanjing Agricultural University, Nanjing, China. ^[5] Clinical Center of Bio-Therapy at Zhongshan Hospital & Institutes of Biomedical Sciences, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. ^[6] Clinical Center for Biotherapy at Zhongshan Hospital, Fudan University, Shanghai, China. ^[7] Shanghai Kelin Clinical Bioinformatics Institute, Shanghai, China. ^[8] LC-Bio Technology Co., Ltd, Hangzhou, China. ^[9] Shanghai Medical College of Fudan University, Fudan University, Shanghai, China. ^[10]

关键词 biomarker cervical cancer immunotherapy response prognosis proteomics